💰 7.7 SEK Million is invested in the Swelife-supported Vinnova-project BRIDGE Sweden, gathering key players from Life Science Sweden’s research infrastructure and innovation system.
On the agenda:
✅ Streamline the road from research to commercialization of biological pharmaceuticals and precision medicine.
✅ Develop new cell lines at SciLifeLab’s DDD platform to bridge the technical gap to Testa Center.
✅ More closely integrate research infrastructure with the innovation system.
Aimed effects:
📍 Ensure that projects can advance from SciLifeLab to Testa Center for GMP, clinical trials, and manufacturing.
📍 Enhance Sweden's international position and attract foreign small businesses to Sweden for development and subsequent production.
📍Guide projects to the next stage after Testa Center, including structures and support functions.
📣 "BRIDGE's combination of research infrastructure and innovation support, syncing business and technical development on the same platform is, as far as we know, unique”, says Alexandra Patriksson, Science Relations Manager, Testa Center.
📣 ”Our goal is to develop stable cell lines for scaling up, this will also lower the investment threshold for these projects." says Per I Arvidsson, Platform Director, SciLifeLab.
🗓️ Project time: 3 years.
🤝 Project partners: Testa Center, SciLifeLab DDD, STUNS Life science ,the Lund Stem Cell Center and pre-GMP unit at Lunds universitet, ALIS (Association of nine Life Science Incubators in Sweden, GU Ventures, KI Innovations AB, LEAD (Business Incubator), Medeon Science Park & Incubator, Sahlgrenska Science Park, SmiLe Venture Hub, Sting, UIC - Uppsala Innovation Centre, Umeå Biotech Incubator).
#lifescience #innovation #commercialization #precisionmedicine